Atypical Diabetic Ketoacidosis: Case Report

Year 2015, Volume: 32 Issue: 1, 124 - 126, 01.01.2015

Hüseyin Demirci Ramazan Coşar İşılay Kalan Sarı

Abstract

Background: Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of diabetes mellitus and can lead to death if untreated. It is a complex metabolic state characterised by hyperglycaemia, acidosis and ketonuria. Bonsai is one of the herbal incense products that contains synthetic cannabinoid and can be easily accessible via the internet in many countries. It cannot be detected in blood and urine studies using conventional methods. Synthetic cannabinoid abuse is associated with severe side effects, including tachycardia, high blood pressure, acidosis, excess sedation and coma. Case Report: A 17-year-old male patient was brought to the emergency department with sudden onset of dyspnoea. Laboratory investigations revealed hyperglycaemia, acidosis and ketonuria. He was admitted to the intensive care unit with a diagnosis of diabetic ketoacidosis. He was not considered a typical case of diabetic ketoacidosis because of the tendency to hypokalaemia, persistent tachycardia and bronchoscopic findings. We learned from his friends that he had used cannabis for a week and used bonzai on the day that he was brought to the emergency service. Conclusion: Diabetic ketoacidosis with prolonged acidosis and tendency to hypokalaemia are investigated for the consumption of synthetic cannabinoids.

Keywords

Cannabinoids, diabetic ketoacidosis, hypokalaemia

References

• 1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-43. [CrossRef]
• 2. Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auwarter V. Acute intoxication by synthetic cannabinoids - Four case reports. Drug Test Anal 2013;5:790-4. [CrossRef]
• 3. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011;11:36-51. [CrossRef]
• 4. Beuck S, Möller I, Thomas A, Klose A, Schlörer N, Schanzer W, et al. Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Anal Bioanal Chem 2011;401:493-505. [CrossRef]
• 5. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011;3:466-78. [CrossRef]
• 6. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60. [CrossRef]
• 7. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005;40:2-14. [CrossRef]
• 8. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 2011;30:351-8. [CrossRef]
• 9. Simmons J, Cookman L, Kang C, Skinner C. Three cases of “spice” exposure. Clinical Toxicol (Phila) 2011;49:431-3. [CrossRef]
• 10. Loschner A, Cihla A, Jalali F, Ghamande S. Diffuse alveolar hemorrhage: add “greenhouse effect” to the growing list. CHEST Journal 2011;140:149A. [CrossRef